Suppr超能文献

关于幽门螺杆菌感染处理的争议。

Controversies regarding management of Helicobacter pylori infections.

机构信息

Texas Tech University Health Science Center, Lubbock.

Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine.

出版信息

Curr Opin Gastroenterol. 2023 Nov 1;39(6):482-489. doi: 10.1097/MOG.0000000000000981. Epub 2023 Sep 5.

Abstract

PURPOSE OF REVIEW

The recognition that Helicobacter pylori should be considered and treated as an infectious disease has yet to fundamentally change diagnostic and treatment practices and has resulted in many controversies.

RECENT FINDINGS

We discuss the following controversies: whether the current 'per-patient' approach to H. pylori testing based on symptoms should be expanded to include achieving population-level H. pylori eradication, whether H. pylori should be approached as an infectious gastrointestinal disease similar to that of other infectious diseases of similar severity and outcome, whether treatment of H. pylori should be primarily empiric or based on antibiotic susceptibility and locally proven successful therapies as are other infectious diseases, whether it is necessary to obtain confirmation of treatment success in every patient treated for H. pylori , and whether potassium-competitive acid blockers should replace proton pump inhibitors in H. pylori therapy.

SUMMARY

Available guidelines and meta-analyses do not yet address H. pylori as an infectious disease. The diagnosis and management and treatment success of H. pylori infections trails behind that of other important infectious diseases. We provide new insights and propose changes in the traditional understanding required to modernize the management of H. pylori infections.

摘要

目的综述

尽管人们已经认识到幽门螺杆菌应被视为一种传染病并加以治疗,但这尚未从根本上改变诊断和治疗实践,并且由此产生了许多争议。

最新研究进展

我们讨论了以下争议:目前基于症状的“个体化”幽门螺杆菌检测方法是否应扩大到包括实现人群层面的幽门螺杆菌根除,是否应将幽门螺杆菌视为一种类似其他严重程度和结局相似的传染性胃肠道疾病,是否应像其他具有相似严重程度和结局的传染性疾病一样,主要根据抗生素敏感性和当地已证明有效的治疗方法来治疗幽门螺杆菌,是否有必要在治疗的每位幽门螺杆菌患者中都确认治疗成功,以及钾竞争性酸阻滞剂是否应替代质子泵抑制剂用于幽门螺杆菌治疗。

总结

现有的指南和荟萃分析并未将幽门螺杆菌视为一种传染病。幽门螺杆菌感染的诊断、管理和治疗成功率落后于其他重要的传染性疾病。我们提供了新的见解,并提出了改变传统观念的建议,以实现幽门螺杆菌感染管理的现代化。

相似文献

1
Controversies regarding management of Helicobacter pylori infections.
Curr Opin Gastroenterol. 2023 Nov 1;39(6):482-489. doi: 10.1097/MOG.0000000000000981. Epub 2023 Sep 5.
2
Sequential versus standard triple first-line therapy for Helicobacter pylori eradication.
Cochrane Database Syst Rev. 2016 Jun 28;2016(6):CD009034. doi: 10.1002/14651858.CD009034.pub2.
3
Non-invasive diagnostic tests for Helicobacter pylori infection.
Cochrane Database Syst Rev. 2018 Mar 15;3(3):CD012080. doi: 10.1002/14651858.CD012080.pub2.
5
Helicobacter pylori and gastric or duodenal ulcer.
Prescrire Int. 2016 Jan;25(167):18-23.
6
The efficacy of adjuvant N acetyl cysteine for the eradication of H pylori infections: A systematic review and meta-analysis of randomized clinical trials.
Clin Res Hepatol Gastroenterol. 2022 Mar;46(3):101832. doi: 10.1016/j.clinre.2021.101832. Epub 2021 Nov 12.
8
Evaluation of guidelines for diagnosis and treatment of Helicobacter pylori infection.
Helicobacter. 2023 Feb;28(1):e12937. doi: 10.1111/hel.12937. Epub 2022 Nov 21.
9
Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people.
Cochrane Database Syst Rev. 2016 Apr 19;4(4):CD003840. doi: 10.1002/14651858.CD003840.pub5.

引用本文的文献

1
An Update on Eradication of in Iran: A Review.
Middle East J Dig Dis. 2024 Jul;16(3):147-154. doi: 10.34172/mejdd.2024.389. Epub 2024 Jul 31.

本文引用的文献

1
Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis.
Lancet Gastroenterol Hepatol. 2023 Jun;8(6):553-564. doi: 10.1016/S2468-1253(23)00070-5. Epub 2023 Apr 20.
2
Implications of the paradigm shift in management of infections.
Therap Adv Gastroenterol. 2023 Mar 18;16:17562848231160858. doi: 10.1177/17562848231160858. eCollection 2023.
3
Why the Vonoprazan Helicobacter pylori Therapies in the US-European Trial Produced Unacceptable Cure Rates.
Dig Dis Sci. 2023 May;68(5):1691-1697. doi: 10.1007/s10620-023-07886-5. Epub 2023 Mar 1.
5
A Population-Based Helicobacter pylori Eradication Strategy Is More Cost-Effective than Endoscopic Screening.
Dig Dis Sci. 2023 May;68(5):1735-1746. doi: 10.1007/s10620-022-07795-z. Epub 2022 Dec 24.
6
The Predictive Performance of Contemporary Guideline Recommendations for Helicobacter pylori Testing in a United States Population.
Clin Gastroenterol Hepatol. 2023 Jul;21(7):1771-1780. doi: 10.1016/j.cgh.2022.10.009. Epub 2022 Oct 18.
7
Helicobacter pylori Antibiotic Resistance in the United States Between 2011 and 2021: A Systematic Review and Meta-Analysis.
Am J Gastroenterol. 2022 Aug 1;117(8):1221-1230. doi: 10.14309/ajg.0000000000001828. Epub 2022 May 5.
8
Diagnosis and Treatment of Infection.
Annu Rev Med. 2022 Jan 27;73:183-195. doi: 10.1146/annurev-med-042220-020814.
9
Antimicrobial Susceptibility Testing for Helicobacter pylori Is Now Widely Available: When, How, Why.
Am J Gastroenterol. 2022 Apr 1;117(4):524-528. doi: 10.14309/ajg.0000000000001659.
10
Chinese Consensus Report on Family-Based Infection Control and Management (2021 Edition).
Gut. 2022 Feb;71(2):238-253. doi: 10.1136/gutjnl-2021-325630. Epub 2021 Nov 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验